The post Eli Lilly secures weight loss drug approval in China: How do rivals stack up? appeared first on Invezz ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

China’s National Medical Products Administration approved Lilly’s shot for long-term weight management on Friday ... regulator initially cleared the drug for diabetes. The shares gained ...

Novo Nordisk announced in June that its weight-loss drug Wegovy received similar approval in China. Eli Lilly and Co. (LLY) announced on its WeChat account Friday that it has won approval from ...

also approved in China, and weight-loss drug Zepbound. Eli Lilly and Novo Nordisk are racing to increase production in a weight-loss market estimated to reach at least $100 billion globally by the ...

A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and the risks. Click for my LLY stock update.

At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...